Roche, Shire court fight underscores high stakes in hemophilia

ZURICH (Reuters) - Roche's bid to muscle in on Shire's share of the $11 billion hemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine.